Week in Review: Hengrui's US Spinoff Funded with $100 Million
June 25, 2016 at 16:52 PM EDT
Hengrui Therapeutics Inc., a New Jersey offshoot of Jiangsu Hengrui Medicine raised $100 million in initial funding from HR Bio Holdings Limited. Initially, HTI will work on US development of three oncology drug candidates from China-Hengrui.